Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: palbociclib capsule: phase 1 and 2 studies, Palbociclib capsule: phase 3 studies, Palbociclib capsule: ICH; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteer
Interventions: GDC-0980, Ketoconazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Blood Pressure
Interventions: BP measurement; Other
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Normal Blood Pressure, Controlled Hypertension, Uncontrolled Hypertension
Interventions: ABPMPro, Spacelabs Ambulatory Blood Pressure Monitoring, Aktiia Blood Pressure, LiveMetric, Bpro; Device
Lead sponsor: Stephen Juraschek; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macular Degeneration
Interventions: pazopanib eye drops, Ketoconozole tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Magnetic Resonance Imaging, Cardiac Pacemaker, Artificial
Interventions: Medtronic Advisa MRI Implantable Pulse Generator (IPG), Medtronic CapSureFix MRI™ active fixation MRI lead; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: Not listed
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Salinas, California • Orlando, Florida • West Des Moines, Iowa + 8 more

Conditions: Brain Diseases
Interventions: Customized version of DAVID device, Blackrock CereStim; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Thrombocytopaenia
Interventions: Eltrombopag, Boceprevir, Telaprevir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Doxorubicin followed by Paclitaxel, Paclitaxel followed by Doxorubicin; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: RSV Infection, Drug Drug Interaction
Interventions: EDP-323, Midazolam, Caffeine, Rosuvastatin; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Leukemia, Acute Lymphoblastic, Multiple Myeloma, Myelofibrosis
Interventions: Molecular diagnostic testing; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pain
Interventions: Oxymorphone; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Autistic Disorder
Interventions: Medical Food : Vayarin_005, Placebo; Other
Lead sponsor: Enzymotec; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Livingston, New Jersey • New York, New York

Conditions: Rectal Adenocarcinoma
Interventions: FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}, Low dose fractionated radiation therapy (LDFRT); Drug · Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Canagliflozin/Placebo Placebo/Canagliflozin, no intervention; Drug · Other
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy Volunteer
Interventions: RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Heart Failure
Interventions: BiDil XR, BiDil Immediate Release (IR); Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Anniston, Alabama • Coral Gables, Florida • Jacksonville, Florida + 2 more

Conditions: Hiv, Pregnancy Related
Interventions: Impact of ring size on adherence; Device
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Presbyopia
Interventions: etafilcon A (multi-focal), etafilcon A (sphere); Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 8
States / cities: Jacksonville, Florida • Sarasota, Florida • Winter Park, Florida + 3 more

Conditions: HSV Infection
Interventions: Pritelivir, ESO and pritelivir; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: ABBV-CLS-7262, Placebo, Moxifloxacin 400mg; Drug
Lead sponsor: Calico Life Sciences LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy Volunteers
Interventions: Midazolam, Cefiderocol; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product

Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

Office Blood Pressure Measurement With an Automated Device

Wearable Evaluation of Ambulatory Readings for Blood Pressure

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

Advisa MRI Clinical Study

Effects of Sensory Flicker and Electrical Flicker Stimulation

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

iCare for Cancer Patients

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety

An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)

Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma

A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets

A Crossover Study Evaluating 3 Non-medicated Silicone IVRs

Handling Comparison Between Two Contact Lens Types

Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants